Literature DB >> 21979318

[Treat-to-target from the perspective of office-based rheumatology].

K Krüger1, K Karberg.   

Abstract

The development of evidence-based treat-to-target (T2T) recommendations alleviates decision-making for the rheumatologist and simultaneously promises substantial improvement of outcome for rheumatoid arthritis (RA) patients. For the office-based rheumatologist in Germany, however, implementation of T2T recommendations contains several difficulties. Limitations arise as a result of an insufficient number of rheumatologists as well as a lack of adequate remuneration both resulting in a lack of time for the individual RA patient. Furthermore budget limitations hinder the appropriate use of antirheumatic drugs and insofar counteract treating to the target of remission. Establishment of selective contracts for rheumatologists by health insurance funds might reduce many of these problems in future for the office-based rheumatologist in Germany.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21979318     DOI: 10.1007/s00393-011-0852-0

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  16 in total

Review 1.  Evidence for predictive validity of remission on long-term outcome in rheumatoid arthritis: a systematic review.

Authors:  Lilian H D van Tuyl; David T Felson; George Wells; Josef Smolen; Bin Zhang; Maarten Boers
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-01-15       Impact factor: 4.794

2.  Trends in treatment and outcomes of rheumatoid arthritis in Germany 1997-2007: results from the National Database of the German Collaborative Arthritis Centres.

Authors:  Stefanie Ziegler; Dörte Huscher; Kirsten Karberg; Andreas Krause; Siegfried Wassenberg; Angela Zink
Journal:  Ann Rheum Dis       Date:  2010-05-06       Impact factor: 19.103

Review 3.  Systematic monitoring of disease activity using an outcome measure improves outcomes in rheumatoid arthritis.

Authors:  Wanruchada Katchamart; Claire Bombardier
Journal:  J Rheumatol       Date:  2010-05-01       Impact factor: 4.666

4.  Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study.

Authors:  Merete Lund Hetland; Kristian Stengaard-Pedersen; Peter Junker; Tine Lottenburger; Torkell Ellingsen; Lis Smedegaard Andersen; Ib Hansen; Henrik Skjødt; Jens Kristian Pedersen; Ulrik Birk Lauridsen; Anders Svendsen; Ulrik Tarp; Jan Pødenphant; Gert Hansen; Hanne Lindegaard; Anselmo de Carvalho; Mikkel Østergaard; Kim Hørslev-Petersen
Journal:  Arthritis Rheum       Date:  2006-05

5.  What do patients want from high-quality general practice and how do we involve them in improvement?

Authors:  Angela Coulter; Glyn Elwyn
Journal:  Br J Gen Pract       Date:  2002-10       Impact factor: 5.386

6.  European patients' views on the responsiveness of health systems and healthcare providers.

Authors:  Angela Coulter; Crispin Jenkinson
Journal:  Eur J Public Health       Date:  2005-06-23       Impact factor: 3.367

Review 7.  From treatment adherence to advanced shared decision making: new professional strategies and attitudes in mental health care.

Authors:  Giuseppe Tibaldi; Luis Salvador-Carulla; Juan Carlos García-Gutierrez
Journal:  Curr Clin Pharmacol       Date:  2011-05

8.  Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry.

Authors:  M L Hetland; H M Lindegaard; A Hansen; J Pødenphant; J Unkerskov; V S Ringsdal; M Østergaard; U Tarp
Journal:  Ann Rheum Dis       Date:  2008-02-13       Impact factor: 19.103

9.  Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.

Authors:  Catriona Grigor; Hilary Capell; Anne Stirling; Alex D McMahon; Peter Lock; Ramsay Vallance; Wilma Kincaid; Duncan Porter
Journal:  Lancet       Date:  2004 Jul 17-23       Impact factor: 79.321

10.  Treating rheumatoid arthritis to target: recommendations of an international task force.

Authors:  Josef S Smolen; Daniel Aletaha; Johannes W J Bijlsma; Ferdinand C Breedveld; Dimitrios Boumpas; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Maarten de Wit; Maxime Dougados; Paul Emery; Alan Gibofsky; Juan Jesus Gomez-Reino; Boulos Haraoui; Joachim Kalden; Edward C Keystone; Tore K Kvien; Iain McInnes; Emilio Martin-Mola; Carlomaurizio Montecucco; Monika Schoels; Désirée van der Heijde; Desirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-03-09       Impact factor: 19.103

View more
  9 in total

1.  [Is treat to target compatible with health insurance and health insurance funds?].

Authors:  J Wendler; E Edelmann
Journal:  Z Rheumatol       Date:  2012-10       Impact factor: 1.372

2.  Quality of care of rural rheumatoid arthritis patients in Austria.

Authors:  Rudolf Puchner; Hans Peter Brezinschek; Manfred Herold; Thomas Nothnagl; Andrea Studnicka-Benke; Josef Fritz; Burkhard F Leeb
Journal:  Wien Klin Wochenschr       Date:  2014-03-28       Impact factor: 1.704

3.  When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS).

Authors:  Emilia Gvozdenović; Cornelia F Allaart; Désirée van der Heijde; Gianfranco Ferraccioli; Josef S Smolen; Tom W J Huizinga; Robert Landewé
Journal:  RMD Open       Date:  2016-04-28

4.  Prioritizing the patient: optimizing therapy in rheumatoid arthritis. Results of a patient questionnaire in northern Germany.

Authors:  Jürgen Wollenhaupt; Inge Ehlebracht-Koenig; André Groenewegen; Dieter Fricke
Journal:  Open Access Rheumatol       Date:  2013-05-15

5.  Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.

Authors:  Josef S Smolen; Monika Schöls; Jürgen Braun; Maxime Dougados; Oliver FitzGerald; Dafna D Gladman; Arthur Kavanaugh; Robert Landewé; Philip Mease; Joachim Sieper; Tanja Stamm; Maarten de Wit; Daniel Aletaha; Xenofon Baraliakos; Neil Betteridge; Filip van den Bosch; Laura C Coates; Paul Emery; Lianne S Gensler; Laure Gossec; Philip Helliwell; Merryn Jongkees; Tore K Kvien; Robert D Inman; Iain B McInnes; Mara Maccarone; Pedro M Machado; Anna Molto; Alexis Ogdie; Denis Poddubnyy; Christopher Ritchlin; Martin Rudwaleit; Adrian Tanew; Bing Thio; Douglas Veale; Kurt de Vlam; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2017-07-06       Impact factor: 19.103

6.  Improving patient flow of people with rheumatoid arthritis has the potential to simultaneously improve health outcomes and reduce direct costs.

Authors:  R Puchner; R Hochreiter; H Pieringer; A Vavrovsky
Journal:  BMC Musculoskelet Disord       Date:  2017-01-07       Impact factor: 2.362

7.  Management of rheumatoid arthritis in Poland - where daily practice might not always meet evidence-based guidelines.

Authors:  Bogdan Batko; Mariusz Korkosz; Anna Juś; Piotr Wiland
Journal:  Arch Med Sci       Date:  2019-03-29       Impact factor: 3.318

8.  DAS steered therapy in clinical practice; cross-sectional results from the METEOR database.

Authors:  Emilia Gvozdenović; Ron Wolterbeek; Désirée van der Heijde; Tom Huizinga; Cornelia Allaart; Robert Landewé
Journal:  BMC Musculoskelet Disord       Date:  2016-01-16       Impact factor: 2.362

9.  Residual disease activity and treatment adjustments in psoriatic arthritis in current clinical practice.

Authors:  Leonieke J J van Mens; Marleen G H van de Sande; Inka A Fluri; Sadaf Atiqi; Arno W R van Kuijk; Dominique L P Baeten
Journal:  Arthritis Res Ther       Date:  2017-10-10       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.